Adaptive Biotechnologies Current Ratio 2018-2021 | ADPT

Adaptive Biotechnologies current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Adaptive Biotechnologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.64B $0.12B 5.52
2021-03-31 $0.77B $0.11B 7.17
2020-12-31 $0.73B $0.11B 6.91
2020-09-30 $0.88B $0.10B 8.70
2020-06-30 $0.60B $0.09B 6.42
2020-03-31 $0.59B $0.08B 7.50
2019-12-31 $0.61B $0.08B 7.82
2019-09-30 $0.60B $0.07B 8.20
2019-06-30 $0.44B $0.08B 5.91
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2017-12-31 $0.21B $0.02B 9.77
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.735B $0.098B
Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76